

Anti-LRRC15 Antibody (Samrotamab Biosimilar)

Cat. No. AB153


Description	
Reactivities	Human/Cynomolgus/Rhesus macaque/Mouse
Target	LRRC15
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	51.7 kDa and 23.4 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
The leucine-rich repeat-containing protein 15 (LRRC15) is involved in cell–cell and cell–matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors.	

Assay Data


Bis-Tris PAGE



Samrotamab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Samrotamab Biosimilar is greater than 95% as determined by SEC-HPLC.

ELISA Data

Samrotamab Biosimilar ELISA

0.2µg Human LRRC15, His Tag Per Well



Immobilized Human LRRC15, His Tag at 2µg/ml (100µl/well) on the plate. Dose response curve for Samrotamab Biosimilar with the EC50 of 6.5ng/ml determined by ELISA.